Quantum Biopharma Files 6-K Report
Ticker: QNTM · Form: 6-K · Filed: Apr 2, 2026 · CIK: 0001771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Apr 2, 2026 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: foreign-issuer, regulatory-filing, press-release
TL;DR
Quantum Biopharma filed a 6-K on 4/2/26 with a press release. Toronto HQ.
AI Summary
Quantum Biopharma Ltd. filed a Form 6-K on April 2, 2026, reporting information as a foreign issuer. The filing includes a press release as Exhibit 99.1. The company's mailing and business address is 55 University Avenue, Suite 1003, Toronto, Ontario, Canada.
Why It Matters
This filing provides updated information for Quantum Biopharma Ltd. as a foreign issuer, which is important for investors tracking the company's regulatory disclosures.
Risk Assessment
Risk Level: low — A 6-K filing is a routine report for foreign issuers and does not inherently indicate significant new risks.
Key Players & Entities
- Quantum Biopharma Ltd. (company) — Filer
- 0001771885 (company) — CIK Number
- 55 UNIVERSITY AVENUE, SUITE 1003 TORONTO Ontario, Canada M5J 2H7 (company) — Mailing and Business Address
- April 2, 2026 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a Form 6-K, which is a report of a foreign issuer.
When was this filing made?
The filing date was April 2, 2026.
What is the company's primary business classification?
The company is classified under SIC code 2834, Pharmaceutical Preparations.
Where is Quantum Biopharma Ltd. located?
The company's mailing and business address is 55 University Avenue, Suite 1003, Toronto, Ontario, Canada.
What document is included as an exhibit?
Exhibit 99.1, a press release, is included with the filing.
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 11.7 · Accepted 2026-04-02 08:30:03
Filing Documents
- f6k_040126.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 5KB
- 0001171843-26-002207.txt ( ) — 12KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: April 2, 2026 /s/ Donal Carroll Donal Carroll Chief Financial Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press Release dated April 2, 2026